CF
DFTX

Corebridge Financial’s Definium Therapeutics DFTX Stock Holding History

Corebridge Financial’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,986
Closed -$211K – 1685
2025
Q1 		$211K Sell
35,986
-4,078
-10% -$29.2K ﹤0.01% 2046
2024
Q4 		$279K Buy
40,064
+1,569
+4% +$10.8K ﹤0.01% 1979
2024
Q3 		$219K Sell
38,495
-238
-0.6% -$1.66K ﹤0.01% 2180
2024
Q2 		$280K Buy
+38,733
New +$339K ﹤0.01% 2004

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corebridge Financial's DFTX Position: Q2 2025 in Review

Corebridge Financial sold out of Definium Therapeutics (DFTX) in Q2 2025, closing a stake of 35,986 shares — an estimated $211K sold.

Corebridge Financial first reported a position in DFTX in Q2 2024 and held it in 4 quarters. The position peaked at $280K in Q2 2024. 181 funds tracked by Wall St. Rank hold DFTX as of Q2 2025.

  • Corebridge Financial reported no remaining Definium Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 35,986 Definium Therapeutics shares in Q2 2025, an estimated $211K.
  • Corebridge Financial first reported a position in Definium Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Definium Therapeutics position peaked at $280K in Q2 2024.
  • 181 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.